Skip to main content
. 2022 Aug 8;9:100434. doi: 10.1016/j.ejro.2022.100434

Fig. 14.

Fig. 14

Immune-mediated thyroiditis in a 65-year-old man with lung cancer on Nivolumab. Contrast-enhanced axial chest CT images show A. Normal appearance of the thyroid before starting Nivolumab. B. There is atrophy of the thyroid with decrease in the enhancement after starting Nivolumab consistent with thyroiditis.